Role of Site Investigator Ensure subject safety is protected & well-managed Full compliance with requirements of Good Clinical Practice (GCP) Conduct the.

Slides:



Advertisements
Similar presentations
Tips to a Successful Monitoring Visit
Advertisements

Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
The Principal Investigator’s Roles and Responsibilities Chicken Soup for the Busy Coordinator (May 2010)
Safety Reporting IN Clinical Trials
Pharmacovigilance Dr. Muiris Dowling,
MONITORING DIFFERENT TYPES OF TRIALS. BY OGUNDOKUN OLUSEGUN BIOMEDICAL SCIENTIST / CLINICAL RESEARCH PROFESSIONAL BMLS (LAUTECH), PGD (Clin. Research.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
Elements of a clinical trial research protocol
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Update: 21 CFR PART 312 FDA Safety Reporting Requirements for INDs
Capturing and Reporting Adverse Events in Clinical Research
ROLE OF NURSES IN CLINICAL RESEARCH IN MALAWI OWEN DAIRE BSCN MPH RNM.
Director, Investigator Support & Integration Services, OCTRI
John Naim, PhD Director Clinical Trials Research Unit
Managing Sponsorship Research Services University of Oxford.
Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.
The Language of Clinical Trials. Objectives Objectives: At the conclusion of this discussion, participants will be able to: –Define clinical research.
Jennifer McCormick MA, CRC Karla Lichter RN CCRC.
MP-7 Investigator Meeting January 31, 2011
SAE Report CTT21 V To:Quality Assurance Research & Development 34 Hyde Terrace LS2 9LN Date:…………………………….. Fax To:+44(0) From (name):………………………..
M ODULE H I NTERIM M ONITORING V ISIT Denise Thwing 21 Apr Version: Final 21-Apr-2010.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Overview of the Clinical Trial & Protocol Jane Fendl March 31, 2010
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Janet Ellen Holwell, CCRC, CCRA President, NY Metropolitan Chapter of ACRP.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
RESPONSIBILITIES OF INVESTIGATOR
1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.
MODULE I Close-Out Visit/Monitoring Reports Jane Fendl April 24, Versions: Final 24-Apr-2010.
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
AE/SAE/EAE Identification and Reporting AE/SAE/EAE Identification and Reporting.
ANJALI JADHAV ANKITA SINGH ANUJA AHIRE ANURADHA PRASAD BEVIN D’SOUZA.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Boehringer Ingelheim Investigator Meeting Study POLO- AML-2 February 23, 2013/Toronto Behbood Sadrolhefazi Therapeutic Area Specialist/ Oncology.
EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.
Agenda Introduction Study Objectives Study Design Delegation
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Office of Human Research Protection Georgia Health Sciences University.
Serious Adverse Event Reporting Start-up Meeting March 25, 2010 Kingston, ON.
D3 ) Not Recovered d5) Fatal Was a post-mortem undertaken?YesNo Was the SAE ongoing at time of death from other cause? Yes No d d m m y y y y d1) Recovered.
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Supervisory Responsibilities of Clinical Investigators
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP

Responsibilities of Sponsor, Investigator and Monitor
MAINTAINING THE INVESTIGATOR’S SITE FILE
Expedited Adverse Event Reporting Requirements
Adverse Event Reporting: Trials and Tribulations
Remote Monitoring of Adverse Events
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
Expedited Adverse Event Reporting Requirements
*Continue on SAE supplemental page CTT21 A if more space is required
Remote Monitoring of Adverse Events
Navigating Non-Compliance
SERIOUS ADVERSE EVENTS REPORTING
MAINTAINING THE INVESTIGATOR’S STUDY FILE
Ramy Abdelrahman, MD Division of Pediatric and Maternal Health (DPMH)
Dr Tim England TICH-2 SAE adjudicator
Good clinical practice
Serious Adverse Event Reconciliation
Presentation transcript:

Role of Site Investigator Ensure subject safety is protected & well-managed Full compliance with requirements of Good Clinical Practice (GCP) Conduct the study in compliance with the protocol

Acknowledge and retain responsibility for study conduct Personally conduct or supervise the clinical study Ensure that all study staff are informed of their obligations (Delegation of Authority) Maintain records of staff qualifications Ensure that mechanisms are in place to ensure that site staff receive the appropriate information throughout the study Ensure that appropriate medical coverage is identified for any planned absences (holiday, attending a conference, etc.) Allow monitoring, auditing & regulatory inspections Notify CERU asap of any planned regulatory inspections Interact with the CERU monitor during monitoring visits Investigator Responsibilities (cont)

Highlighted Responsibilities Site Investigator/sub-I delegate should sign/date all documentation to make the following assessments: Confirmation of patient eligibility SAE Identification & Assessment Ensure adherence to reporting requirements & timelines Provide causality assessment Determine relationship to investigational product Perform Severity of Burn and Grafting Assessments

GRAFTING ASSESSMENT (Post-Enrollment) Initial Grafting Assessment (to be completed after consent is obtained) Deep Partial/Full Thickness Burn expected to require grafting: __________%TBSA Final Grafting Assessment (to be completed at the end of study duration) Total Body Surface Area that actually required grafting: __________%TBSA

Any untoward medical event that: Results in death, Is life-threatening, Requires hospitalization or prolongation of hospitalization, Results in disability/incapacity, Is a congenital anomaly/birth defect, A medically important event (e.g. one that may result in an intervention to prevent one of above outcomes) Serious Adverse Events (SAEs)

SAE Identification Unexpected event - is NOT expected due to the progression of the underlying disease or co-morbid illnesses. Not all deaths – only unexpected. Related to the Study Intervention defined as: Possibly Related: suggests that the association of this SAE with the study supplement is unknown and the event is not reasonable supported by other conditions. Probably Related: suggests that a reasonable temporal sequence of this SAE with study supplement administration exists and the association of the event with the study supplement seems likely. Report SERIOUS Adverse Events that are: 1. Unexpected – regardless of relationship to intervention 2. Related to Intervention – regardless of expectedness

Subject Withdrawal A subject may be withdrawn from IP at any time: at SDM or her/his own request, or at the discretion of the investigator for safety, behavioral or administrative reasons. A subject may withdraw (or be withdrawn) from the study prematurely for the following reasons: Serious Adverse Event related to intervention Termination of the study by the sponsor Other (must be specified)

Delegation of Authority Logs “The Investigator should maintain a list of appropriately qualified persons to whom the investigator has delegated significant trial-related duties (ICH section 4.1.5)” Completed Log to be sent to CERU before start of trial